Biotec Pharmacon ASA Strengthens Its Patent Coverage

Biotec Pharmacon ASA announced that the Company has been issued two patents that cover the combination of monoclonal antibodies and yeast beta glucan for treatment of a large variety of cancers by the Japanese and the Indian Patent Offices. The patents cover a pharmaceutical combination for the treatment of cancer expressing certain antigens comprising as active ingredients a complement-activating antibody capable of binding to certain antigens, and a beta-glucan defined by its structure and/or its origin.